| Overview |
| bsm-61813r-apc-cy5 |
| GCSAM Recombinant Monoclonal Antibody, APC-Cy5 Conjugated |
| FCM, IF(ICC) |
| Human |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GCSAM |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 257144 |
| Q8N6F7 |
| Cytoplasm, Cell membrane |
| GCAT2; Gcet; Gcsam; hGAL; M17; M17 L. |
| Involved in the negative regulation of lymphocyte motility. It mediates the migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK kinase activation. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz